GnRH agonist leuprolide depot 3-month
Selected indexed studies
- Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. (J Clin Endocrinol Metab, 2012) [PMID:22344198]
- Clinical pharmacokinetics of depot leuprorelin. (Clin Pharmacokinet, 2002) [PMID:12083977]
- 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty. (J Clin Endocrinol Metab, 2014) [PMID:24926950]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Clinical pharmacokinetics of depot leuprorelin. (2002) pubmed
- Comparison of efficacy and safety of 1- and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer. (2013) pubmed
- Leuprorelin acetate granulomas: case reports and review of the literature. (2005) pubmed
- Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. (2012) pubmed
- 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty. (2014) pubmed
- Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer. (2009) pubmed
- Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. (2002) pubmed
- Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). (2002) pubmed
- Fixed Dosing of Leuprolide Acetate, a GnRH Agonist, in Children with Central Precocious Puberty: A Population Pharmacokinetic Justification. (2026) pubmed
- A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer. (2021) pubmed